Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Assets: 2023-2025

Historic Current Assets for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $279.9 million.

  • Immunome's Current Assets rose 14.70% to $279.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.9 million, marking a year-over-year increase of 14.70%. This contributed to the annual value of $221.3 million for FY2024, which is 52.96% up from last year.
  • Immunome's Current Assets amounted to $279.9 million in Q3 2025, which was up 0.90% from $277.4 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Current Assets ranged from a high of $323.1 million in Q1 2025 and a low of $39.5 million during Q2 2023.
  • Its 3-year average for Current Assets is $206.0 million, with a median of $244.0 million in 2024.
  • As far as peak fluctuations go, Immunome's Current Assets skyrocketed by 619.23% in 2024, and later decreased by 2.41% in 2025.
  • Over the past 3 years, Immunome's Current Assets (Quarterly) stood at $144.7 million in 2023, then surged by 52.96% to $221.3 million in 2024, then increased by 14.70% to $279.9 million in 2025.
  • Its Current Assets stands at $279.9 million for Q3 2025, versus $277.4 million for Q2 2025 and $323.1 million for Q1 2025.